Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
1-A
1-A POS
1-A-W
1-A/A
1-K
1-K/A
1-SA
1-SA/A
1-U
1-U/A
1-Z
1-Z-W
1-Z/A
1/A
10-12B
10-12B/A
10-12G
10-12G/A
10-D
10-D/A
10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QSB
10-QSB/A
10-QT
10-QT/A
10KSB
11-K
11-K/A
11-KT
13F-HR
13F-HR/A
13F-NT
13F-NT/A
13FCONP
144
144/A
15-12B
15-12B/A
15-12G
15-12G/A
15-15D
15-15D/A
15F-12B
15F-12G
15F-12G/A
15F-15D
18-K
18-K/A
19B-4E
2-E
20-F
20-F/A
20FR12B
20FR12B/A
20FR12G/A
24F-2NT
24F-2NT/A
25
25-NSE
25-NSE/A
25/A
253G1
253G2
253G3
3
3/A
305B2
305B2/A
4
4/A
40-17F1
40-17F1/A
40-17F2
40-17F2/A
40-17G
40-17G/A
40-202A
40-202A/A
40-206A
40-24B2
40-33
40-6B
40-6B/A
40-6C
40-6C/A
40-8B25
40-8F-2/A
40-APP
40-APP/A
40-F
40-F/A
40-OIP
40-OIP/A
40FR12B
40FR12B/A
424B1
424B2
424B3
424B4
424B5
424B7
424B8
424H
424H/A
425
485APOS
485B24E
485BPOS
485BXT
486APOS
486BPOS
486BXT
487
497
497AD
497J
497K
5
5/A
6-K
6-K/A
8-A12B
8-A12B/A
8-A12G
8-A12G/A
8-K
8-K/A
8-K12B
8-K12B/A
8-K12G3
8-K12G3/A
8-K15D5
8-K15D5/A
8-M
9-M
ABS-15G
ABS-15G/A
ABS-EE
ABS-EE/A
ADV-E
ADV-H-C
ADV-H-T
ADV-NR
ANNLRPT
APP NTC
APP ORDR
APP WD
APP WD/A
ARS
ARS/A
ATS-N
ATS-N/CA
ATS-N/MA
ATS-N/UA
AW
AW WD
C
C-AR
C-AR-W
C-AR/A
C-TR
C-U
C-U-W
C-W
C/A
C/A-W
CB
CB/A
CERT
CERTARCA
CERTBATS
CERTCBO
CERTNAS
CERTNYS
CERTPAC
CFPORTAL
CFPORTAL/A
CORRESP
CT ORDER
D
D/A
DEF 14A
DEF 14C
DEF13E3
DEF13E3/A
DEFA14A
DEFA14C
DEFC14A
DEFC14A
DEFC14C
DEFM14A
DEFM14C
DEFN14A
DEFR14A
DEFR14C
DEFS14A
DEFS14C
DEL AM
DFAN14A
DFRN14A
DOS/A
DSTRBRPT
DSTRBRPT/A
EFFECT
F-1
F-1/A
F-10
F-10/A
F-10EF
F-1MEF
F-3
F-3/A
F-3ASR
F-3D
F-4
F-4/A
F-6
F-6 POS
F-6/A
F-6EF
F-7
F-8 POS
F-80
F-N
F-X
F-X/A
FOCUSN
FOCUSN/A
FWP
G-405
G-FIN/A
IRANNOTICE
MA
MA-A
MA-I
MA-I/A
MA-W
MA/A
MSD
MSD/A
N-14
N-14 8C
N-14 8C/A
N-14/A
N-14MEF
N-18F1
N-1A
N-1A/A
N-2
N-2/A
N-23C-2
N-23C3A
N-23C3B
N-2MEF
N-30B-2
N-30D
N-30D/A
N-4
N-4/A
N-54A
N-54C
N-6
N-6/A
N-6F
N-8A
N-8A/A
N-8B-2/A
N-8F
N-8F NTC
N-8F ORDR
N-8F/A
N-CEN
N-CEN/A
N-CSR
N-CSR/A
N-CSRS
N-CSRS/A
N-MFP2
N-MFP2/A
N-PX
N-PX/A
N-Q
N-Q/A
NO ACT
NPORT-P
NPORT-P/A
NRSRO-CE
NRSRO-CE/A
NRSRO-UPD
NSAR-A
NSAR-A/A
NSAR-AT
NSAR-B
NSAR-B/A
NSAR-BT
NSAR-U
NSAR-U/A
NT 10-K
NT 10-K/A
NT 10-Q
NT 10-Q/A
NT 11-K
NT 20-F
NT 20-F/A
NT N-CEN
NT N-MFP2
NT NPORT-EX
NT-NCSR
NT-NCSR/A
NT-NSAR
NT-NSAR/A
NTFNCSR
NTN 10Q
POS 8C
POS AM
POS AMI
POS EX
POS462B
POSASR
PRE 14A
PRE 14C
PREC14A
PREC14C
PREM14A
PREM14C
PREN14A
PRER14A
PRER14C
PRRN14A
PX14A6G
QRTLYRPT
QUALIF
REG-NR
REGDEX
REGDEX/A
REVOKED
RW
RW WD
S-1
S-1/A
S-11
S-11/A
S-11MEF
S-1MEF
S-1MEF
S-3
S-3/A
S-3ASR
S-3D
S-3DPOS
S-3MEF
S-4
S-4 POS
S-4/A
S-4MEF
S-6
S-6/A
S-8
S-8 POS
S-B
S-B/A
SC 13D
SC 13D/A
SC 13E
SC 13E/A
SC 13E1
SC 13E1/A
SC 13E3
SC 13E3/A
SC 13E4
SC 13E4/A
SC 13G
SC 13G/A
SC 14D9
SC 14D9/A
SC 14F1
SC TO-C
SC TO-I
SC TO-I/A
SC TO-T
SC TO-T/A
SC14D9C
SD
SD/A
SDR/A
SE
SEC STAFF
SEC STAFF ACTION
SEC STAFF LETTER
SF-1/A
SF-3
SF-3/A
SUPPL
T-3
T-3/A
TA-1
TA-1/A
TA-2
TA-2/A
TA-W
UPLOAD
WDL-REQ
X-17A-5
X-17A-5/A
Tags
Inv. presentation
Quarterly results
iTeos Therapeutics, Inc. (ITOS)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
03/24/2021
8-K
Quarterly results
11/12/2020
8-K
Quarterly results
Docs:
"
Enrollment continues in Phase 1/2a clinical trial in adult patients with advanced solid tumors: The multi-arm Phase 1/2a clinical trial of EOS-850 trial in adult patients with advanced solid tumors is ongoing. In addition to the single-agent cohort, dosing has also commenced in the second cohort evaluating EOS-850 in combination with pembrolizumab. The COVID-19 pandemic has resulted in the Company experiencing enrollment delays for its third cohort evaluating EOS-850 in combination with chemotherapy. The Company is now opening additional sites in the U.S., France, Spain and South Korea to support continued enrollment and expects to dose the first patient in the chemotherapy cohort by the end of 2020. The Company remains on-track to report initial single-agent and combination data in the fi...
",
"
iTeos Appoints Matthew Roden, Ph.D. to Board of Directors
",
"
A2AR 0.7 12 222 17 A1R 192 39 185 61 A2BR 575
"
09/01/2020
8-K
Quarterly results
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy